Latest On Galectin Therapeutics, Inc (GALT):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-27 15:45 EST | News | Galectin Therapeutics Rides Roller-Coaster Of Volatility | N/A |  |
| 2023-05-15 10:14 EST | News | Galectin Therapeutics GAAP EPS of -$0.19 | N/A | |
| 2023-03-31 04:59 EST | News | Galectin Therapeutics GAAP EPS of -$0.65 in-line | N/A | |
| 2023-03-16 18:06 EST | News | Galectin gets safety board nod to continue trial of liver disease drug belapectin | N/A | |
| 2023-01-03 16:10 EST | News | Galectin Therapeutics: In For A Long 2-Year Wait | N/A | |
| 2022-11-22 20:32 EST | News | Galectin Therapeutics (GALT) Investor Presentation - Slideshow | N/A | |
| 2022-11-14 09:02 EST | News | Galectin Therapeutics GAAP EPS of -$0.14 | N/A | |
| 2022-10-12 20:35 EST | News | Galectin rises as FDA approves to begin human trial of combination immunotherapy in head and neck cancer | N/A | |
| 2022-08-15 15:35 EST | News | Galectin Therapeutics GAAP EPS of -$0.16 | N/A | |
| 2022-07-11 19:26 EST | News | Galectin: Ability To Potentially Target Unmet Medical Need | N/A | |
| 2022-05-16 12:17 EST | News | Galectin Therapeutics GAAP EPS of -$0.17 | N/A | |
| 2022-04-14 22:54 EST | News | Independent safety board recommends continuing Galectin's NAVIGATE trial without changes | N/A | |
| 2022-03-31 10:51 EST | News | Galectin Therapeutics GAAP EPS of -$0.52 beats by $0.07 | N/A | |
| 2021-11-16 01:20 EST | News | Galectin Therapeutics EPS beats by $0.04 | N/A | |
| 2021-09-21 18:44 EST | News | Galectin Therapeutics announces $20M convertible debt financing from its Chairman | N/A | |
| 2021-08-17 13:44 EST | News | Galectin Therapeutics expands NASH trial for Belapectin despite COVID-19 impact | N/A | |
| 2021-07-21 09:23 EST | News | Galectin: Pursuing A Subset In The NASH Space | N/A | |
| 2021-07-21 09:17 EST | News | Galectin Therapeutics shares soar on early-stage Belapectin cancer study data | N/A | |
| 2021-07-21 09:13 EST | News | Allied Healthcare Products, SCWorx leads healthcare gainers; Meridian Bioscience, Aridis Pharmaceuticals among major losers | N/A | |
| 2021-04-20 05:26 EST | News | Galectin Therapeutics jumps 16%, world-renowned Dr. Ben Carson joins as special consultant | N/A | |
| 2021-04-17 07:03 EST | News | Galectin Therapeutics: The Galectin Signature - Signed, Sealed, And About To Be Delivered | N/A | |
| 2021-04-14 07:56 EST | News | Galectin's belapectin + Keytruda enhances tumor response in melanoma, head/neck cancer | N/A | |
| 2021-04-06 21:07 EST | News | Galectin Therapeutics launches navigatenash.com | N/A | |
| 2021-03-31 21:24 EST | News | Galectin Therapeutics EPS beats by $0.02 | N/A | |
| 2020-11-26 20:06 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-13 12:05 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-12 11:49 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-10 11:57 EST | Earnings Estimate | An EPS average of -$0.16 is estimated for the quarter ending on March 31, 2021. | Sell | |
| 2020-11-09 09:01 EST | News | Galectin Therapeutics reports Q3 results | N/A | |
| 2020-11-07 15:54 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-03 08:20 EST | Insider Trade | JOEL LEWIS has directly acquired 6,562 shares and currently holds 130,886 shares. | Buy | |
| 2020-10-19 17:21 EST | Insider Trade | JOEL LEWIS has directly acquired 5,807 shares and currently holds 124,324 shares. | Buy | |
| 2020-10-15 17:05 EST | Insider Trade | 10X Fund, L.P. has directly disposed of 10,000 shares and currently holds 6,356,440 shares. | Sell | |
| 2020-10-08 16:54 EST | Analyst Rating | The Analyst Target Price has increased from $8 to $12. | Buy | |
| 2020-10-02 08:05 EST | Insider Trade | JOEL LEWIS has directly acquired 6,242 shares and currently holds 118,517 shares. | Buy | |
| 2020-09-26 12:51 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 21:21 EST | Insider Trade | JOEL LEWIS has directly acquired 5,171 shares and currently holds 112,275 shares. | Buy | |
| 2020-09-17 04:58 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-09 08:36 EST | Insider Trade | Richard E Uihlein has directly acquired 10,000 shares and currently holds 7,893,191 shares. | Buy | |
| 2020-09-09 08:36 EST | Insider Trade | KEVIN D FREEMAN has acquired 5,000 shares indirectly via a limited liability company controlled the Reporting Person: Freeman Global Holdings, LLC. | Buy | |
| 2020-08-14 16:45 EST | Analyst Rating | The Analyst Target Price has increased from $6.5 to $8. | Buy | |
| 2020-08-14 08:54 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-12 04:50 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 01:05 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 17:07 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 08:48 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-07 08:40 EST | News | Intercept's Pain Is Galectin's Gain: Clinical Outcomes In NASH Are Crucial | N/A | |
| 2020-07-01 03:48 EST | News | Galectin launches new study of lead drug in NASH | N/A | |
| 2020-06-26 08:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 04:50 EST | Financials | Company financials have been released. | Neutral | |
About Galectin Therapeutics, Inc (GALT):
Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate is GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. The company was founded in 2000 and is based in Norcross, Georgia.
General
- Name Galectin Therapeutics, Inc
- Symbol GALT
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 4
- Last Split Factor1:6
- Last Split Date2012-03-23
- Fiscal Year EndDecember
- IPO Date2002-09-09
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://galectintherapeutics.com
View More
Valuation
- Price/Book (Most Recent Quarter) 4.56
View More
Financials
- Most Recent Quarter 2020-09-30
- Next Quarter EPS Estimate -$0.15
- Return on Assets -31%
- Return on Equity -51%
- Earnings Per Share -$0.42
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 135.27 million
- Analyst Target Price $12
- Book Value Per Share $0.51
View More
Share Statistics
- Shares Outstanding 57.08 million
- Shares Float 41.22 million
- % Held by Insiders 2901%
- % Held by Institutions 17.35%
- Shares Short 4.63 million
- Shares Short Prior Month 4.67 million
- Short Ratio 11.48
- Short % of Float 20%
- Short % of Shares Outstanding 8%
View More
Technicals
- Beta 2.03
- 52 Week High $3.74
- 52 Week Low $1.62
- 50 Day Moving Average 2.29
- 200 Day Moving Average 2.52
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Galectin Therapeutics, Inc (GALT) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Galectin Therapeutics, Inc (GALT) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-11-09 | $N/A | -$0.10 | -$0.14 | 28.57% |
| 2020-06-30 | 2020-08-10 | $N/A | -$0.11 | -$0.07 | -57.14% |
| 2020-03-31 | 2020-05-11 | $N/A | -$0.06 | -$0.09 | 33.33% |
| 2019-12-31 | 2020-03-16 | $N/A | -$0.12 | -$0.06 | -100% |
| 2019-09-30 | 2019-11-12 | $N/A | -$0.05 | -$0.10 | 50% |
| 2019-06-30 | 2019-08-09 | $N/A | -$0.06 | -$0.12 | 50% |
| 2019-03-31 | 2019-05-10 | $N/A | -$0.20 | -$0.14 | -42.86% |
| 2018-12-31 | 2019-03-06 | $N/A | -$0.08 | -$0.08 | 0% |
| 2018-09-30 | 2018-11-13 | $N/A | -$0.07 | -$0.09 | 22.22% |
| 2018-06-30 | 2018-08-14 | $N/A | -$0.11 | -$0.12 | 4.35% |
| 2018-03-31 | 2018-05-11 | $N/A | -$0.12 | -$0.13 | 7.69% |
| 2017-12-31 | 2018-03-29 | $N/A | -$0.07 | -$0.11 | 38.22% |
| 2017-09-30 | 2017-11-07 | $N/A | -$0.13 | -$0.14 | 9.28% |
| 2017-06-30 | 2017-08-14 | $N/A | -$0.14 | -$0.15 | 6.67% |
| 2017-03-31 | 2017-05-15 | $N/A | -$0.15 | -$0.16 | 3.23% |
| 2016-12-31 | 2017-03-28 | $N/A | -$0.12 | -$0.17 | 29.41% |
| 2016-09-30 | 2016-11-08 | $N/A | -$0.19 | -$0.22 | 12.32% |
| 2016-06-30 | 2016-08-09 | $N/A | -$0.20 | -$0.24 | 16.67% |
| 2016-03-31 | 2016-05-10 | $N/A | -$0.24 | -$0.19 | -26.32% |
| 2015-12-31 | 2016-03-15 | $N/A | -$0.19 | -$0.24 | 20.83% |
| 2015-09-30 | 2015-11-09 | $N/A | -$0.26 | -$0.20 | -30% |
| 2015-06-30 | 2015-08-10 | $N/A | -$0.21 | -$0.23 | 8.7% |
| 2015-03-31 | 2015-05-11 | $N/A | -$0.22 | -$0.20 | -10% |
| 2014-12-31 | 2015-03-18 | $N/A | -$0.18 | -$0.17 | -5.88% |
| 2014-09-30 | 2014-11-10 | $N/A | -$0.17 | -$0.26 | 34.62% |
| 2014-06-30 | 2014-08-07 | $N/A | -$0.17 | -$0.21 | 19.05% |
| 2014-03-31 | 2014-05-13 | $N/A | -$0.25 | -$0.20 | -25% |
| 2013-12-31 | 2014-03-21 | $N/A | -$0.15 | -$0.18 | 16.67% |
| 2013-09-30 | 2013-11-12 | $N/A | -$0.22 | -$0.19 | -15.79% |
| 2013-06-30 | 2013-08-14 | $N/A | -$0.18 | -$0.18 | 0% |
| 2013-03-31 | 2013-05-10 | $N/A | -$0.22 | -$0.18 | -22.22% |
| 2012-12-31 | 2013-03-31 | $N/A | -$0.17 | -$0.21 | 19.05% |
| 2012-09-30 | 2012-11-09 | $N/A | -$0.19 | -$0.18 | -5.56% |
| 2012-06-30 | 2012-08-10 | $N/A | -$0.19 | -$0.16 | -18.75% |
| 2012-03-31 | 2012-05-14 | $N/A | -$0.17 | ||
| 2011-12-31 | 2012-03-30 | $N/A | -$0.29 | -$0.21 | -38.1% |
| 2011-09-30 | 2011-11-10 | $N/A | -$0.18 | -$0.24 | 25% |
| 2011-06-30 | 2011-08-12 | $N/A | -$0.36 | -$0.18 | -100% |
| 2011-03-31 | 2011-05-13 | $N/A | -$0.24 | ||
| 2010-12-31 | 2011-03-15 | $N/A | -$0.16 | ||
| 2010-09-30 | 2010-11-12 | $N/A | -$0.18 | -$0.09 | -100% |
| 2010-06-30 | 2010-08-13 | $N/A | -$0.28 | ||
| 2010-03-31 | 2010-05-12 | $N/A | -$0.34 | ||
| 2009-12-31 | 2010-03-12 | $N/A | -$0.18 | -$0.13 | -38.46% |
| 2009-09-30 | 2009-11-13 | $N/A | -$0.24 | ||
| 2009-06-30 | 2009-08-14 | $N/A | -$0.42 | -$0.22 | -90.91% |
| 2009-03-31 | 2009-05-15 | $N/A | -$0.36 | -$0.14 | -157.14% |
| 2008-09-30 | 2008-11-07 | $N/A | $0.02 | ||
| 2008-06-30 | 2008-08-08 | $N/A | -$0.08 | ||
| 2008-03-31 | 2008-05-15 | $N/A | -$0.29 | ||
| 2007-12-31 | 2008-03-28 | $N/A | -$0.18 | ||
| 2007-09-30 | 2007-11-14 | $N/A | -$0.36 | ||
| 2007-06-30 | 2007-08-10 | $N/A | $0.01 | -$0.30 | 101.8% |
| 2007-03-31 | 2007-05-15 | $N/A | -$0.96 | ||
| 2006-09-30 | 2006-11-13 | $N/A | $0.10 | ||
| 2006-06-30 | 2006-08-14 | $N/A | -$0.46 | ||
| 2006-03-31 | 2006-05-22 | $N/A | -$1.61 | ||
| 2005-12-31 | 2006-03-10 | $N/A | -$0.38 | ||
| 2005-09-30 | 2005-11-10 | $N/A | -$0.37 | ||
| 2005-06-30 | 2005-08-05 | $N/A | -$0.37 | ||
| 2005-03-31 | 2005-05-13 | $N/A | -$0.31 | ||
| 2004-09-30 | 2004-11-10 | $N/A | -$0.40 | ||
| 2004-06-30 | 2004-08-05 | $N/A | -$0.33 | ||
| 2004-03-31 | 2004-04-29 | $N/A | -$0.46 | ||
| 2003-12-31 | 2004-03-30 | $N/A | -$0.42 | ||
| 2003-09-30 | 2003-11-14 | $N/A | -$0.37 | ||
| 2003-06-30 | 2003-08-14 | $N/A | -$0.29 | ||
| 2003-03-31 | 2003-05-14 | $N/A | -$0.28 | ||
| 2002-12-31 | 2002-12-31 | $N/A | -$0.41 | ||
| 2002-09-30 | 2002-09-30 | $N/A | -$0.25 |
Galectin Therapeutics, Inc (GALT) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Galectin Therapeutics, Inc (GALT) Chart:
Galectin Therapeutics, Inc (GALT) News:
Below you will find a list of latest news for Galectin Therapeutics, Inc (GALT) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Galectin Therapeutics, Inc (GALT) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 2.5 | 0.95 | CALL | 25 | 487 | 103.07 | TRUE | -0.04 | -0.04 |
| 2024-05-17 | 5 | 0.1 | CALL | 0 | 90 | 117.19 | FALSE | 0 | 0 |
| 2024-05-17 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 2.5 | 0.05 | PUT | 0 | 52 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 5 | 1.65 | PUT | 1 | 2 | 100.98 | TRUE | 1.65 | 0 |
| 2024-05-17 | 7.5 | 0 | PUT | 0 | 0 | 282.07 | TRUE | 0 | 0 |
| 2024-06-21 | 2.5 | 0 | CALL | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-06-21 | 5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 2.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 5 | 0 | PUT | 0 | 0 | 334.83 | TRUE | 0 | 0 |
| 2024-06-21 | 7.5 | 0 | PUT | 0 | 0 | 569.98 | TRUE | 0 | 0 |
| 2024-07-19 | 2.5 | 1.05 | CALL | 31 | 681 | 79.17 | TRUE | -0.05 | -0.05 |
| 2024-07-19 | 5 | 0.23 | CALL | 10 | 10398 | 94.95 | FALSE | 0.03 | 0.15 |
| 2024-07-19 | 7.5 | 0.1 | CALL | 0 | 134 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 2.5 | 0.14 | PUT | 0 | 14 | 99.26 | FALSE | 0 | 0 |
| 2024-07-19 | 5 | 1.76 | PUT | 0 | 2 | 103.79 | TRUE | 0 | 0 |
| 2024-07-19 | 7.5 | 0 | PUT | 0 | 0 | 180.92 | TRUE | 0 | 0 |
| 2024-10-18 | 2.5 | 1.25 | CALL | 3 | 664 | 84.26 | TRUE | -0.49 | -0.28 |
| 2024-10-18 | 5 | 0.45 | CALL | 11 | 636 | 90.92 | FALSE | -0.05 | -0.1 |
| 2024-10-18 | 7.5 | 0.2 | CALL | 1 | 366 | 94.98 | FALSE | -0.05 | -0.2 |
| 2024-10-18 | 2.5 | 0.3 | PUT | 0 | 3 | 90.64 | FALSE | 0 | 0 |
| 2024-10-18 | 5 | 0 | PUT | 0 | 0 | 107.97 | TRUE | 0 | 0 |
| 2024-10-18 | 7.5 | 0 | PUT | 0 | 0 | 115.78 | TRUE | 0 | 0 |
Latest GALT Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:51 PM EST | 41 | $1.34 |
| Jun 13, 2022 7:57 PM EST | 1 | $1.35 |
| Jun 13, 2022 7:57 PM EST | 1 | $1.35 |
| Jun 13, 2022 7:59 PM EST | 100 | $1.35 |
| Jun 13, 2022 7:59 PM EST | 65 | $1.34 |
Galectin Therapeutics, Inc (GALT) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133416/000119312520183351/0001193125-20-183351-index.htm |
| 2019-03-08 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1133416/000000000019004300/0000000000-19-004300-index.htm |
| 2019-08-22 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1133416/000000000019012760/0000000000-19-012760-index.htm |
| 2020-05-18 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1133416/000000000020004404/0000000000-20-004404-index.htm |
| 2019-09-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000089924319023102/0000899243-19-023102-index.htm |
| 2019-09-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000089924319023110/0000899243-19-023110-index.htm |
| 2019-11-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000089924319027471/0000899243-19-027471-index.htm |
| 2020-01-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000089924320001112/0000899243-20-001112-index.htm |
| 2020-01-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000089924320001114/0000899243-20-001114-index.htm |
| 2020-01-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000089924320001115/0000899243-20-001115-index.htm |
| 2020-01-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000089924320001119/0000899243-20-001119-index.htm |
| 2020-01-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000089924320001120/0000899243-20-001120-index.htm |
| 2020-01-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000089924320001121/0000899243-20-001121-index.htm |
| 2020-01-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000089924320001125/0000899243-20-001125-index.htm |
| 2020-01-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000089924320001127/0000899243-20-001127-index.htm |
| 2020-01-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000089924320001128/0000899243-20-001128-index.htm |
| 2020-01-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000089924320001131/0000899243-20-001131-index.htm |
| 2020-02-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000089924320003828/0000899243-20-003828-index.htm |
| 2020-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000089924320004591/0000899243-20-004591-index.htm |
| 2020-03-16 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000089924320008452/0000899243-20-008452-index.htm |
| 2020-03-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000089924320008455/0000899243-20-008455-index.htm |
| 2020-03-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000089924320009061/0000899243-20-009061-index.htm |
| 2020-09-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000089924320023805/0000899243-20-023805-index.htm |
| 2020-09-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000089924320024606/0000899243-20-024606-index.htm |
| 2020-09-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000089924320024607/0000899243-20-024607-index.htm |
| 2020-09-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000089924320025606/0000899243-20-025606-index.htm |
| 2020-10-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000089924320026798/0000899243-20-026798-index.htm |
| 2020-10-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000089924320028629/0000899243-20-028629-index.htm |
| 2020-11-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000089924320030173/0000899243-20-030173-index.htm |
| 2019-01-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000009/0001179022-19-000009-index.htm |
| 2019-01-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000010/0001179022-19-000010-index.htm |
| 2019-01-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000011/0001179022-19-000011-index.htm |
| 2019-01-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000012/0001179022-19-000012-index.htm |
| 2019-01-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000013/0001179022-19-000013-index.htm |
| 2019-01-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000014/0001179022-19-000014-index.htm |
| 2019-01-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000015/0001179022-19-000015-index.htm |
| 2019-01-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000016/0001179022-19-000016-index.htm |
| 2019-01-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000017/0001179022-19-000017-index.htm |
| 2019-01-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000018/0001179022-19-000018-index.htm |
| 2019-01-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000019/0001179022-19-000019-index.htm |
| 2019-01-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000020/0001179022-19-000020-index.htm |
| 2019-01-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000021/0001179022-19-000021-index.htm |
| 2019-01-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000022/0001179022-19-000022-index.htm |
| 2019-01-31 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000023/0001179022-19-000023-index.htm |
| 2019-02-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000024/0001179022-19-000024-index.htm |
| 2019-02-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000025/0001179022-19-000025-index.htm |
| 2019-02-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000026/0001179022-19-000026-index.htm |
| 2019-02-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000027/0001179022-19-000027-index.htm |
| 2019-04-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000028/0001179022-19-000028-index.htm |
| 2019-04-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000029/0001179022-19-000029-index.htm |
| 2019-04-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000030/0001179022-19-000030-index.htm |
| 2019-04-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000031/0001179022-19-000031-index.htm |
| 2019-06-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000032/0001179022-19-000032-index.htm |
| 2019-06-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000033/0001179022-19-000033-index.htm |
| 2019-06-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000034/0001179022-19-000034-index.htm |
| 2019-06-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000035/0001179022-19-000035-index.htm |
| 2019-06-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000036/0001179022-19-000036-index.htm |
| 2019-06-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000037/0001179022-19-000037-index.htm |
| 2019-06-03 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000038/0001179022-19-000038-index.htm |
| 2019-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000039/0001179022-19-000039-index.htm |
| 2018-09-28 | 10-K/A | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1133416/000119312518287503/0001193125-18-287503-index.htm |
| 2018-09-28 | 10-Q/A | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1133416/000119312518287515/0001193125-18-287515-index.htm |
| 2018-11-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1133416/000119312518324862/0001193125-18-324862-index.htm |
| 2018-11-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133416/000119312518324871/0001193125-18-324871-index.htm |
| 2018-12-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133416/000119312518353923/0001193125-18-353923-index.htm |
| 2019-01-03 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/1133416/000119312519001150/0001193125-19-001150-index.htm |
| 2019-01-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133416/000119312519009410/0001193125-19-009410-index.htm |
| 2019-01-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133416/000119312519014852/0001193125-19-014852-index.htm |
| 2019-03-06 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1133416/000119312519064705/0001193125-19-064705-index.htm |
| 2019-03-06 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1133416/000119312519064707/0001193125-19-064707-index.htm |
| 2019-03-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133416/000119312519064710/0001193125-19-064710-index.htm |
| 2019-03-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133416/000119312519064711/0001193125-19-064711-index.htm |
| 2019-03-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133416/000119312519064717/0001193125-19-064717-index.htm |
| 2019-03-20 | S-3/A | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1133416/000119312519080960/0001193125-19-080960-index.htm |
| 2019-03-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133416/000119312519082272/0001193125-19-082272-index.htm |
| 2019-04-08 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1133416/000119312519100750/0001193125-19-100750-index.htm |
| 2019-04-08 | S-3/A | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1133416/000119312519100784/0001193125-19-100784-index.htm |
| 2019-04-10 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1133416/000119312519102634/0001193125-19-102634-index.htm |
| 2019-04-10 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1133416/000119312519102831/0001193125-19-102831-index.htm |
| 2019-04-12 | S-3/A | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1133416/000119312519104607/0001193125-19-104607-index.htm |
| 2019-04-12 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1133416/000119312519104900/0001193125-19-104900-index.htm |
| 2019-04-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133416/000119312519105791/0001193125-19-105791-index.htm |
| 2019-04-30 | 424B1 | Prospectus [Rule 424(b)(1)] | https://www.sec.gov/Archives/edgar/data/1133416/000119312519128940/0001193125-19-128940-index.htm |
| 2019-05-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1133416/000119312519143642/0001193125-19-143642-index.htm |
| 2019-05-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133416/000119312519143648/0001193125-19-143648-index.htm |
| 2019-05-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133416/000119312519143652/0001193125-19-143652-index.htm |
| 2019-05-10 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses | https://www.sec.gov/Archives/edgar/data/1133416/000119312519143655/0001193125-19-143655-index.htm |
| 2019-05-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133416/000119312519157698/0001193125-19-157698-index.htm |
| 2019-08-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133416/000119312519212557/0001193125-19-212557-index.htm |
| 2019-08-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1133416/000119312519217477/0001193125-19-217477-index.htm |
| 2019-08-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133416/000119312519217490/0001193125-19-217490-index.htm |
| 2019-08-09 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1133416/000119312519218036/0001193125-19-218036-index.htm |
| 2019-08-20 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1133416/000119312519224832/0001193125-19-224832-index.htm |
| 2019-09-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133416/000119312519246270/0001193125-19-246270-index.htm |
| 2019-09-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133416/000119312519256643/0001193125-19-256643-index.htm |
| 2019-10-17 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1133416/000119312519268920/0001193125-19-268920-index.htm |
| 2019-11-12 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1133416/000119312519289288/0001193125-19-289288-index.htm |
| 2019-11-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133416/000119312519289295/0001193125-19-289295-index.htm |
| 2019-11-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133416/000119312519300519/0001193125-19-300519-index.htm |
| 2019-12-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133416/000119312519305851/0001193125-19-305851-index.htm |
| 2019-12-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133416/000119312519307822/0001193125-19-307822-index.htm |
| 2020-02-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133416/000119312520042697/0001193125-20-042697-index.htm |
| 2020-03-16 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1133416/000119312520073907/0001193125-20-073907-index.htm |
| 2020-03-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133416/000119312520073919/0001193125-20-073919-index.htm |
| 2020-03-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133416/000119312520075484/0001193125-20-075484-index.htm |
| 2020-04-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133416/000119312520127814/0001193125-20-127814-index.htm |
| 2020-05-11 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1133416/000119312520138168/0001193125-20-138168-index.htm |
| 2020-05-11 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1133416/000119312520138283/0001193125-20-138283-index.htm |
| 2020-05-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133416/000119312520138286/0001193125-20-138286-index.htm |
| 2020-05-19 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1133416/000119312520146100/0001193125-20-146100-index.htm |
| 2020-06-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133416/000119312520181006/0001193125-20-181006-index.htm |
| 2020-06-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133416/000119312520183351/0001193125-20-183351-index.htm |
| 2020-08-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1133416/000119312520214127/0001193125-20-214127-index.htm |
| 2020-08-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133416/000119312520214130/0001193125-20-214130-index.htm |
| 2020-09-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133416/000119312520237638/0001193125-20-237638-index.htm |
| 2020-09-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133416/000119312520250649/0001193125-20-250649-index.htm |
| 2020-09-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133416/000119312520257779/0001193125-20-257779-index.htm |
| 2020-10-19 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1133416/000119312520271677/0001193125-20-271677-index.htm |
| 2019-04-01 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1133416/000149315219004543/0001493152-19-004543-index.htm |
| 2019-04-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000149315219004630/0001493152-19-004630-index.htm |
| 2019-04-01 | 5 | Annual statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000149315219004632/0001493152-19-004632-index.htm |
| 2019-04-02 | 5 | Annual statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000149315219004665/0001493152-19-004665-index.htm |
| 2019-06-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000149315219009040/0001493152-19-009040-index.htm |
| 2019-07-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000149315219011073/0001493152-19-011073-index.htm |
| 2019-10-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000149315219015454/0001493152-19-015454-index.htm |
| 2020-01-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000149315220000877/0001493152-20-000877-index.htm |
| 2020-02-13 | 5 | Annual statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000149315220002223/0001493152-20-002223-index.htm |
| 2020-02-13 | 5 | Annual statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000149315220002229/0001493152-20-002229-index.htm |
| 2020-10-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133416/000149315220019507/0001493152-20-019507-index.htm |
| 2019-04-12 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1133416/999999999519000692/9999999995-19-000692-index.htm |
| 2019-08-22 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1133416/999999999519001949/9999999995-19-001949-index.htm |
| 2020-05-21 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1133416/999999999520001237/9999999995-20-001237-index.htm |
Galectin Therapeutics, Inc (GALT) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Galectin Therapeutics, Inc (GALT). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 2901%Institutional Ownership: 1735%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-02-09 | JOEL LEWIS | Director | Buy | 8,000.00 | 2.39 | 19,120.00 | 107,104.00 | https://www.sec.gov/Archives/edgar/data/1133416/000089924320003828/0000899243-20-003828-index.htm |
| 2019-09-06 | KEVIN D FREEMAN | Director | Buy | 1,290.00 | 3.71 | 4,785.90 | 11,000.00 | https://www.sec.gov/Archives/edgar/data/1133416/000089924319023102/0000899243-19-023102-index.htm |
| 2020-09-15 | JOEL LEWIS | President and CEO | Buy | 5,171.00 | 2.93 | 15,151.03 | 112,275.00 | https://www.sec.gov/Archives/edgar/data/1133416/000089924320025606/0000899243-20-025606-index.htm |
| 2020-09-30 | JOEL LEWIS | President and CEO | Buy | 6,242.00 | 2.67 | 16,666.14 | 118,517.00 | https://www.sec.gov/Archives/edgar/data/1133416/000089924320026798/0000899243-20-026798-index.htm |
| 2020-10-15 | JOEL LEWIS | President and CEO | Buy | 5,807.00 | 2.87 | 16,666.09 | 124,324.00 | https://www.sec.gov/Archives/edgar/data/1133416/000089924320028629/0000899243-20-028629-index.htm |
| 2019-09-05 | GILBERT F AMELIO | Director | Sell | 30,000.00 | 3.30 | 99,000.00 | 124,614.00 | https://www.sec.gov/Archives/edgar/data/1133416/000089924319023110/0000899243-19-023110-index.htm |
| 2020-10-30 | JOEL LEWIS | President and CEO | Buy | 6,562.00 | 2.54 | 16,667.48 | 130,886.00 | https://www.sec.gov/Archives/edgar/data/1133416/000089924320030173/0000899243-20-030173-index.htm |
| 2019-02-21 | Marc Rubin | Director | Sell | 7,000.00 | 6.00 | 42,000.00 | 13,581.00 | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000027/0001179022-19-000027-index.htm |
| 2019-02-21 | Marc Rubin | Director | Sell | 43,326.00 | 6.02 | 261,026.15 | 13,581.00 | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000027/0001179022-19-000027-index.htm |
| 2019-02-22 | Marc Rubin | Director | Sell | 859.00 | 6.02 | 5,174.96 | 13,581.00 | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000027/0001179022-19-000027-index.htm |
| 2019-11-15 | KEVIN D FREEMAN | Director | Buy | 3,000.00 | 3.36 | 10,075.80 | 14,000.00 | https://www.sec.gov/Archives/edgar/data/1133416/000089924319027471/0000899243-19-027471-index.htm |
| 2019-02-22 | Marc Rubin | Director | Buy | 859.00 | 2.39 | 2,053.01 | 14,440.00 | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000027/0001179022-19-000027-index.htm |
| 2019-02-08 | KEVIN D FREEMAN | Director | Buy | 1,500.00 | 4.29 | 6,427.50 | 1,500.00 | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000025/0001179022-19-000025-index.htm |
| 2019-01-31 | GILBERT F AMELIO | Director | Sell | 13,047.00 | 5.00 | 65,235.00 | 154,614.00 | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000024/0001179022-19-000024-index.htm |
| 2019-01-21 | GILBERT F AMELIO | Director | Buy | 41,500.00 | 0.89 | 36,935.00 | 161,461.00 | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000020/0001179022-19-000020-index.htm |
| 2019-01-30 | GILBERT F AMELIO | Director | Sell | 16,953.00 | 5.00 | 84,765.00 | 167,661.00 | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000024/0001179022-19-000024-index.htm |
| 2019-04-05 | KEVIN D FREEMAN | Director | Buy | 500.00 | 4.73 | 2,365.00 | 2,000.00 | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000028/0001179022-19-000028-index.htm |
| 2020-03-19 | KEVIN D FREEMAN | Director | Buy | 6,000.00 | 1.64 | 9,844.20 | 20,000.00 | https://www.sec.gov/Archives/edgar/data/1133416/000089924320009061/0000899243-20-009061-index.htm |
| 2019-01-21 | GILBERT F AMELIO | Director | Buy | 62,250.00 | 2.39 | 148,777.50 | 215,935.00 | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000020/0001179022-19-000020-index.htm |
| 2019-05-31 | KEVIN D FREEMAN | Director | Buy | 1,426.00 | 4.28 | 6,103.28 | 23,469.00 | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000035/0001179022-19-000035-index.htm |
| 2020-09-04 | KEVIN D FREEMAN | Director | Buy | 5,000.00 | 2.57 | 12,848.00 | 25,000.00 | https://www.sec.gov/Archives/edgar/data/1133416/000089924320024607/0000899243-20-024607-index.htm |
| 2019-01-16 | Richard E Uihlein | Director | Buy | 7,415.00 | 4.72 | 34,998.80 | 2,535,289.00 | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000019/0001179022-19-000019-index.htm |
| 2019-01-28 | Richard E Uihlein | Director | Buy | 3,000.00 | 4.77 | 14,315.10 | 2,538,289.00 | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000021/0001179022-19-000021-index.htm |
| 2019-01-29 | Richard E Uihlein | Director | Buy | 48,500.00 | 4.87 | 236,243.50 | 2,586,789.00 | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000021/0001179022-19-000021-index.htm |
| 2019-04-05 | Richard E Uihlein | Director | Buy | 21,000.00 | 4.81 | 100,972.20 | 2,607,789.00 | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000029/0001179022-19-000029-index.htm |
| 2019-04-09 | Richard E Uihlein | Director | Buy | 20,700.00 | 4.82 | 99,850.59 | 2,628,489.00 | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000031/0001179022-19-000031-index.htm |
| 2019-05-31 | Richard E Uihlein | Director | Buy | 7,710.00 | 4.28 | 32,998.80 | 27,710.00 | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000032/0001179022-19-000032-index.htm |
| 2019-05-29 | Richard E Uihlein | Director | Buy | 500,000.00 | 5.00 | 2,500,000.00 | 3,128,489.00 | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000032/0001179022-19-000032-index.htm |
| 2019-05-31 | JACK W CALLICUTT | Chief Financial Officer | Buy | 2,354.00 | 4.28 | 10,075.12 | 3,614.00 | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000037/0001179022-19-000037-index.htm |
| 2019-05-31 | KARY ELDRED | Director | Buy | 3,033.00 | 4.28 | 12,981.24 | 44,415.00 | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000036/0001179022-19-000036-index.htm |
| 2019-02-21 | Marc Rubin | Director | Buy | 43,326.00 | 2.39 | 103,549.14 | 56,907.00 | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000027/0001179022-19-000027-index.htm |
| 2019-01-16 | JOEL LEWIS | Director | Buy | 11,653.00 | 4.72 | 55,002.16 | 63,133.00 | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000018/0001179022-19-000018-index.htm |
| 2020-10-13 | 10X Fund, L.P. | 10% Share Holder | Sell | 10,000.00 | 2.97 | 29,700.00 | 6,356,440.00 | https://www.sec.gov/Archives/edgar/data/1133416/000149315220019507/0001493152-20-019507-index.htm |
| 2020-01-17 | 10X Fund, L.P. | 10% Share Holder | Sell | 10,000.00 | 2.97 | 29,700.00 | 6,375,790.00 | https://www.sec.gov/Archives/edgar/data/1133416/000149315220000877/0001493152-20-000877-index.htm |
| 2019-10-10 | 10X Fund, L.P. | 10% Share Holder | Sell | 17,000.00 | 3.73 | 63,325.00 | 6,385,790.00 | https://www.sec.gov/Archives/edgar/data/1133416/000149315219015454/0001493152-19-015454-index.htm |
| 2019-01-29 | JOEL LEWIS | Director | Buy | 1,000.00 | 4.81 | 4,805.00 | 64,133.00 | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000022/0001179022-19-000022-index.htm |
| 2019-02-07 | JOEL LEWIS | Director | Buy | 1,000.00 | 4.48 | 4,484.10 | 65,133.00 | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000026/0001179022-19-000026-index.htm |
| 2019-04-05 | JOEL LEWIS | Director | Buy | 667.00 | 4.82 | 3,214.07 | 65,800.00 | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000030/0001179022-19-000030-index.htm |
| 2019-05-31 | GILBERT S OMENN | Director | Buy | 18,578.00 | 4.28 | 79,513.84 | 66,769.00 | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000034/0001179022-19-000034-index.htm |
| 2019-05-31 | Richard E Uihlein | Director | Buy | 4,672,896.00 | 4.28 | 19,999,994.88 | 7,801,385.00 | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000032/0001179022-19-000032-index.htm |
| 2020-01-09 | Richard E Uihlein | Director | Buy | 12,238.00 | 2.86 | 35,000.68 | 7,817,678.00 | https://www.sec.gov/Archives/edgar/data/1133416/000089924320001131/0000899243-20-001131-index.htm |
| 2020-02-13 | Richard E Uihlein | Director | Buy | 46,875.00 | 2.39 | 112,031.25 | 7,864,553.00 | https://www.sec.gov/Archives/edgar/data/1133416/000089924320004591/0000899243-20-004591-index.htm |
| 2019-05-31 | JOEL LEWIS | Director | Buy | 12,849.00 | 4.28 | 54,993.72 | 78,649.00 | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000033/0001179022-19-000033-index.htm |
| 2020-02-13 | Richard E Uihlein | Director | Buy | 18,638.00 | 4.72 | 87,971.36 | 7,883,191.00 | https://www.sec.gov/Archives/edgar/data/1133416/000089924320004591/0000899243-20-004591-index.htm |
| 2020-09-04 | Richard E Uihlein | Director | Buy | 10,000.00 | 2.55 | 25,500.00 | 7,893,191.00 | https://www.sec.gov/Archives/edgar/data/1133416/000089924320024606/0000899243-20-024606-index.htm |
| 2019-06-04 | Harold H. Shlevin | Chief Executive Officer | Buy | 8,706.00 | 1.37 | 11,927.22 | 8,706.00 | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000039/0001179022-19-000039-index.htm |
| 2019-05-31 | KEVIN D FREEMAN | Director | Buy | 7,710.00 | 4.28 | 32,998.80 | 9,710.00 | https://www.sec.gov/Archives/edgar/data/1133416/000117902219000035/0001179022-19-000035-index.htm |
| 2020-01-09 | JOEL LEWIS | Director | Buy | 20,455.00 | 2.86 | 58,501.30 | 99,104.00 | https://www.sec.gov/Archives/edgar/data/1133416/000089924320001128/0000899243-20-001128-index.htm |